دوره انگلیسی برای گزارش عوارض دارویی همراه با فلش‌کارت آموزشی — ارائه روی فلش مموری

🎓 دوره آموزشی جامع

📚 اطلاعات دوره

عنوان دوره: دوره انگلیسی برای گزارش عوارض دارویی

موضوع کلی: آموزش زبان‌های خارجی

موضوع میانی: زبان در حوزه پزشکی

📋 سرفصل‌های دوره

• 1. Introduction to Pharmacovigilance Terminology
• 2. Basic English Grammar for Medical Professionals
• 3. Understanding Medical English Sentence Structure
• 4. Common Medical Prefixes and Suffixes
• 5. Anatomy and Physiology Basics for Pharmacovigilance
• 6. Core Medical Vocabulary Related to Diseases
• 7. Vocabulary for Common Symptoms (Pain, Fever, etc.)
• 8. Vocabulary for Gastrointestinal System
• 9. Vocabulary for Cardiovascular System
• 10. Vocabulary for Respiratory System
• 11. Vocabulary for Neurological System
• 12. Vocabulary for Dermatological System
• 13. Vocabulary for Musculoskeletal System
• 14. Vocabulary for Endocrine System
• 15. Vocabulary for Urogenital System
• 16. Vocabulary for Hematological System
• 17. Vocabulary for Immune System
• 18. Vocabulary for Ophthalmological System
• 19. Vocabulary for Otolaryngological System
• 20. Vocabulary for Psychiatric Conditions
• 21. Vocabulary for Infectious Diseases
• 22. Vocabulary for Malignancies
• 23. Medical Abbreviations and Acronyms
• 24. Units of Measurement in Medicine
• 25. Time and Frequency Expressions in Medical Reports
• 26. Introduction to Drug Classifications
• 27. Generic vs. Brand Names of Drugs
• 28. Routes of Drug Administration
• 29. Dosage Forms and Strengths
• 30. Pharmacokinetics: Absorption, Distribution, Metabolism, Excretion (ADME)
• 31. Pharmacodynamics: Drug Action and Effects
• 32. Mechanism of Action (MOA) of Common Drug Classes
• 33. Adverse Drug Reactions (ADRs): Definitions and Classifications
• 34. Types of ADRs: Allergic, Idiosyncratic, Dose-Related
• 35. Severity of ADRs: Mild, Moderate, Severe
• 36. Seriousness Criteria for ADRs (Hospitalization, Life-Threatening)
• 37. Causality Assessment: Likelihood of a Drug Causing an ADR
• 38. MedDRA: Medical Dictionary for Regulatory Activities - Introduction
• 39. MedDRA: Preferred Terms (PTs)
• 40. MedDRA: High-Level Terms (HLTs) and High-Level Group Terms (HLGTs)
• 41. MedDRA: System Organ Classes (SOCs)
• 42. Coding ADRs using MedDRA
• 43. Reporting Period and Follow-up Information
• 44. Patient Demographics in ADR Reports
• 45. Patient Medical History
• 46. Concomitant Medications
• 47. Allergies and Past Adverse Reactions
• 48. Drug Information: Name, Dose, Frequency, Route, Start/End Dates
• 49. Adverse Event Description: Onset, Duration, Severity, Outcome
• 50. Signs and Symptoms of ADRs
• 51. Diagnostic Tests and Investigations
• 52. Laboratory Results Related to ADRs
• 53. Imaging Studies in ADR Assessment
• 54. Treatment of ADRs
• 55. Management of Specific ADRs
• 56. Intervention Taken (Drug Discontinuation, Dose Adjustment)
• 57. Outcome of ADRs: Recovered, Recovering, Not Recovered, Fatal
• 58. Dechallenge and Rechallenge Information
• 59. Reporting Organization and Reporter Details
• 60. Source of Information (Spontaneous, Literature, Clinical Trial)
• 61. Regulatory Authority Reporting Requirements (FDA, EMA, etc.)
• 62. Timelines for ADR Reporting
• 63. Standardized ADR Report Forms (e.g., CIOMS I, MedWatch)
• 64. Completing Section 1: Reporter and Patient Information
• 65. Completing Section 2: Suspect Product(s)
• 66. Completing Section 3: Adverse Event(s)
• 67. Completing Section 4: Outcome of Event(s)
• 68. Completing Section 5: Dechallenge and Rechallenge
• 69. Completing Section 6: Concomitant Illnesses and Other Treatmemt
• 70. Completing Section 7: Pregnancy and Nursing Information
• 71. Completing Section 8: Relevant Medical History
• 72. Completing Section 9: Seriousness Criteria Justification
• 73. Completing Section 10: Causality Assessment
• 74. Writing Clear and Concise ADR Descriptions
• 75. Using Objective Language in ADR Reports
• 76. Avoiding Subjective or Vague Statements
• 77. Quantifying Symptoms and Findings
• 78. Specifying Drug Names and Dosages Accurately
• 79. Documenting Dates and Times of Events
• 80. Referring to Medical Literature for Support
• 81. Ethical Considerations in ADR Reporting
• 82. Confidentiality and Data Privacy
• 83. Understanding Pharmacovigilance Databases
• 84. Data Entry and Validation Procedures
• 85. Signal Detection: Identifying Potential Safety Issues
• 86. Risk Management Plans (RMPs)
• 87. Benefit-Risk Assessment
• 88. Post-Marketing Surveillance
• 89. Periodic Safety Update Reports (PSURs)
• 90. Investigational Medicinal Products (IMPs)
• 91. Specific ADRs of Commonly Used Drug Classes (e.g., Antibiotics, Antihypertensives)
• 92. Drug-Induced Liver Injury (DILI)
• 93. Drug-Induced Kidney Injury (DIKI)
• 94. Cardiotoxicity
• 95. Neurotoxicity
• 96. Hematological ADRs
• 97. Hypersensitivity Reactions
• 98. Drug Interactions and Their Impact on ADRs
• 99. Pediatric Pharmacovigilance Considerations
• 100. Geriatric Pharmacovigilance Considerations